{
  "input": {
    "mode": "revise",
    "query": {
      "entity": "Generalised pustular psoriasis",
      "relation": "indication"
    },
    "tegraph_snapshot": {
      "nodes": [
        {
          "id": "n_acitretin",
          "type": "Drug",
          "label": "Acitretin",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "n_apremilast",
          "type": "Drug",
          "label": "Apremilast",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "n_etanercept",
          "type": "Drug",
          "label": "Etanercept",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "n_infliximab",
          "type": "Drug",
          "label": "Infliximab",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "n_secukinumab",
          "type": "Drug",
          "label": "Secukinumab",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "n_cyclosporine",
          "type": "Drug",
          "label": "Cyclosporine",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "n_methotrexate",
          "type": "Drug",
          "label": "Methotrexate",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "n_adalimumab",
          "type": "Drug",
          "label": "Adalimumab",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "n_il17_inhibitors",
          "type": "Drug",
          "label": "Interleukin-17 inhibitors",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "n_topical_corticosteroids",
          "type": "Drug",
          "label": "Topical corticosteroids",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "n_ustekinumab",
          "type": "Drug",
          "label": "Ustekinumab",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "n_thalidomide",
          "type": "Drug",
          "label": "Thalidomide",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "n_gpp",
          "type": "Disease",
          "label": "Generalised pustular psoriasis",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "n_target_inflammation",
          "type": "Target",
          "label": "Inflammation Pathway",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "n_target_immunomodulation",
          "type": "Target",
          "label": "Immunomodulation Pathway",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "n_ot_acitretin",
          "type": "Target",
          "label": "OffTarget Acitretin",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "n_ot_apremilast",
          "type": "Target",
          "label": "OffTarget Apremilast",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "n_ot_etanercept",
          "type": "Target",
          "label": "OffTarget Etanercept",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "n_ot_infliximab",
          "type": "Target",
          "label": "OffTarget Infliximab",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "n_ot_secukinumab",
          "type": "Target",
          "label": "OffTarget Secukinumab",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "n_ot_cyclosporine",
          "type": "Target",
          "label": "OffTarget Cyclosporine",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "n_ot_methotrexate",
          "type": "Target",
          "label": "OffTarget Methotrexate",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "n_ot_adalimumab",
          "type": "Target",
          "label": "OffTarget Adalimumab",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "n_ot_il17_inhibitors",
          "type": "Target",
          "label": "OffTarget IL-17 Inhibitors",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "n_ot_topical_corticosteroids",
          "type": "Target",
          "label": "OffTarget Topical Corticosteroids",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "n_ot_ustekinumab",
          "type": "Target",
          "label": "OffTarget Ustekinumab",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "n_ot_thalidomide",
          "type": "Target",
          "label": "OffTarget Thalidomide",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "n_rp",
          "type": "Pathway",
          "label": "Risk Pathway",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "n_adv",
          "type": "Phenotype",
          "label": "Adverse Phenotype",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "H1",
          "type": "Hypothesis",
          "label": "Acitretin",
          "attrs": {
            "agent": "PI"
          }
        },
        {
          "id": "drug_acitretin",
          "type": "Drug",
          "label": "Acitretin",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "H2",
          "type": "Hypothesis",
          "label": "Apremilast",
          "attrs": {
            "agent": "PI"
          }
        },
        {
          "id": "drug_apremilast",
          "type": "Drug",
          "label": "Apremilast",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "H3",
          "type": "Hypothesis",
          "label": "Etanercept",
          "attrs": {
            "agent": "PI"
          }
        },
        {
          "id": "drug_etanercept",
          "type": "Drug",
          "label": "Etanercept",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "H4",
          "type": "Hypothesis",
          "label": "Infliximab",
          "attrs": {
            "agent": "PI"
          }
        },
        {
          "id": "drug_infliximab",
          "type": "Drug",
          "label": "Infliximab",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "H5",
          "type": "Hypothesis",
          "label": "Secukinumab",
          "attrs": {
            "agent": "PI"
          }
        },
        {
          "id": "drug_secukinumab",
          "type": "Drug",
          "label": "Secukinumab",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "H6",
          "type": "Hypothesis",
          "label": "Cyclosporine",
          "attrs": {
            "agent": "PI"
          }
        },
        {
          "id": "drug_cyclosporine",
          "type": "Drug",
          "label": "Cyclosporine",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "H7",
          "type": "Hypothesis",
          "label": "Methotrexate",
          "attrs": {
            "agent": "PI"
          }
        },
        {
          "id": "drug_methotrexate",
          "type": "Drug",
          "label": "Methotrexate",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "H8",
          "type": "Hypothesis",
          "label": "Adalimumab",
          "attrs": {
            "agent": "PI"
          }
        },
        {
          "id": "drug_adalimumab",
          "type": "Drug",
          "label": "Adalimumab",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "H9",
          "type": "Hypothesis",
          "label": "Interleukin-17 inhibitors",
          "attrs": {
            "agent": "PI"
          }
        },
        {
          "id": "drug_interleukin_17_inhibitors",
          "type": "Drug",
          "label": "Interleukin-17 inhibitors",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "H10",
          "type": "Hypothesis",
          "label": "Topical corticosteroids",
          "attrs": {
            "agent": "PI"
          }
        },
        {
          "id": "drug_topical_corticosteroids",
          "type": "Drug",
          "label": "Topical corticosteroids",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "H11",
          "type": "Hypothesis",
          "label": "Ustekinumab",
          "attrs": {
            "agent": "PI"
          }
        },
        {
          "id": "drug_ustekinumab",
          "type": "Drug",
          "label": "Ustekinumab",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "H12",
          "type": "Hypothesis",
          "label": "Thalidomide",
          "attrs": {
            "agent": "PI"
          }
        },
        {
          "id": "drug_thalidomide",
          "type": "Drug",
          "label": "Thalidomide",
          "attrs": {
            "agent": "Proponent"
          }
        }
      ],
      "edges": [
        {
          "source": "n_acitretin",
          "target": "n_target_inflammation",
          "relation": "acts_on",
          "weight": 0.85,
          "agent": "Proponent",
          "rationale": "常用于处理炎症相关疾病"
        },
        {
          "source": "n_apremilast",
          "target": "n_target_immunomodulation",
          "relation": "acts_on",
          "weight": 0.85,
          "agent": "Proponent",
          "rationale": "调节免疫反应，有助于治疗"
        },
        {
          "source": "n_etanercept",
          "target": "n_target_inflammation",
          "relation": "acts_on",
          "weight": 0.85,
          "agent": "Proponent",
          "rationale": "靶向 TNF-α，炎症相关"
        },
        {
          "source": "n_infliximab",
          "target": "n_target_inflammation",
          "relation": "acts_on",
          "weight": 0.85,
          "agent": "Proponent",
          "rationale": "强效抗TNF-α药物，适用于炎症性疾病"
        },
        {
          "source": "n_secukinumab",
          "target": "n_target_immunomodulation",
          "relation": "acts_on",
          "weight": 0.85,
          "agent": "Proponent",
          "rationale": "IL-17 抑制剂，对免疫有调节作用"
        },
        {
          "source": "n_cyclosporine",
          "target": "n_target_immunomodulation",
          "relation": "acts_on",
          "weight": 0.75,
          "agent": "Proponent",
          "rationale": "免疫抑制剂，常用于自身免疫性疾病"
        },
        {
          "source": "n_methotrexate",
          "target": "n_target_immunomodulation",
          "relation": "acts_on",
          "weight": 0.75,
          "agent": "Proponent",
          "rationale": "经典的免疫抑制剂"
        },
        {
          "source": "n_adalimumab",
          "target": "n_target_inflammation",
          "relation": "acts_on",
          "weight": 0.85,
          "agent": "Proponent",
          "rationale": "用于治疗多种炎症性疾病"
        },
        {
          "source": "n_il17_inhibitors",
          "target": "n_target_immunomodulation",
          "relation": "acts_on",
          "weight": 0.85,
          "agent": "Proponent",
          "rationale": "抑制 IL-17 以改善免疫反应"
        },
        {
          "source": "n_topical_corticosteroids",
          "target": "n_target_inflammation",
          "relation": "acts_on",
          "weight": 0.8,
          "agent": "Proponent",
          "rationale": "局部用药，快速缓解炎症"
        },
        {
          "source": "n_ustekinumab",
          "target": "n_target_immunomodulation",
          "relation": "acts_on",
          "weight": 0.8,
          "agent": "Proponent",
          "rationale": "靶向 IL-12/23 途径，调节免疫"
        },
        {
          "source": "n_thalidomide",
          "target": "n_target_immunomodulation",
          "relation": "acts_on",
          "weight": 0.75,
          "agent": "Proponent",
          "rationale": "调节免疫，减少炎症反应"
        },
        {
          "source": "n_target_inflammation",
          "target": "n_gpp",
          "relation": "involved_in",
          "weight": 0.85,
          "agent": "Proponent",
          "rationale": "炎症与 GPP 相关"
        },
        {
          "source": "n_target_immunomodulation",
          "target": "n_gpp",
          "relation": "involved_in",
          "weight": 0.85,
          "agent": "Proponent",
          "rationale": "免疫调节与 GPP 关系密切"
        },
        {
          "source": "drug_acitretin",
          "target": "n_ot_acitretin",
          "relation": "acts_on",
          "weight": 0.7,
          "agent": "Skeptic",
          "rationale": "可能对未靶向组织产生影响"
        },
        {
          "source": "drug_apremilast",
          "target": "n_ot_apremilast",
          "relation": "acts_on",
          "weight": 0.7,
          "agent": "Skeptic",
          "rationale": "可能对未靶向组织产生影响"
        },
        {
          "source": "drug_etanercept",
          "target": "n_ot_etanercept",
          "relation": "acts_on",
          "weight": 0.7,
          "agent": "Skeptic",
          "rationale": "可能对未靶向组织产生影响"
        },
        {
          "source": "drug_infliximab",
          "target": "n_ot_infliximab",
          "relation": "acts_on",
          "weight": 0.7,
          "agent": "Skeptic",
          "rationale": "可能对未靶向组织产生影响"
        },
        {
          "source": "drug_secukinumab",
          "target": "n_ot_secukinumab",
          "relation": "acts_on",
          "weight": 0.7,
          "agent": "Skeptic",
          "rationale": "可能对未靶向组织产生影响"
        },
        {
          "source": "drug_cyclosporine",
          "target": "n_ot_cyclosporine",
          "relation": "acts_on",
          "weight": 0.7,
          "agent": "Skeptic",
          "rationale": "可能对未靶向组织产生影响"
        },
        {
          "source": "drug_methotrexate",
          "target": "n_ot_methotrexate",
          "relation": "acts_on",
          "weight": 0.7,
          "agent": "Skeptic",
          "rationale": "可能对未靶向组织产生影响"
        },
        {
          "source": "drug_adalimumab",
          "target": "n_ot_adalimumab",
          "relation": "acts_on",
          "weight": 0.7,
          "agent": "Skeptic",
          "rationale": "可能对未靶向组织产生影响"
        },
        {
          "source": "drug_interleukin_17_inhibitors",
          "target": "n_ot_il17_inhibitors",
          "relation": "acts_on",
          "weight": 0.7,
          "agent": "Skeptic",
          "rationale": "可能对未靶向组织产生影响"
        },
        {
          "source": "drug_topical_corticosteroids",
          "target": "n_ot_topical_corticosteroids",
          "relation": "acts_on",
          "weight": 0.7,
          "agent": "Skeptic",
          "rationale": "可能对未靶向组织产生影响"
        },
        {
          "source": "drug_ustekinumab",
          "target": "n_ot_ustekinumab",
          "relation": "acts_on",
          "weight": 0.7,
          "agent": "Skeptic",
          "rationale": "可能对未靶向组织产生影响"
        },
        {
          "source": "drug_thalidomide",
          "target": "n_ot_thalidomide",
          "relation": "acts_on",
          "weight": 0.7,
          "agent": "Skeptic",
          "rationale": "可能对未靶向组织产生影响"
        },
        {
          "source": "n_ot_acitretin",
          "target": "n_rp",
          "relation": "involved_in",
          "weight": 0.7,
          "agent": "Skeptic",
          "rationale": "风险通路关联"
        },
        {
          "source": "n_ot_apremilast",
          "target": "n_rp",
          "relation": "involved_in",
          "weight": 0.7,
          "agent": "Skeptic",
          "rationale": "风险通路关联"
        },
        {
          "source": "n_ot_etanercept",
          "target": "n_rp",
          "relation": "involved_in",
          "weight": 0.7,
          "agent": "Skeptic",
          "rationale": "风险通路关联"
        },
        {
          "source": "n_ot_infliximab",
          "target": "n_rp",
          "relation": "involved_in",
          "weight": 0.7,
          "agent": "Skeptic",
          "rationale": "风险通路关联"
        },
        {
          "source": "n_ot_secukinumab",
          "target": "n_rp",
          "relation": "involved_in",
          "weight": 0.7,
          "agent": "Skeptic",
          "rationale": "风险通路关联"
        },
        {
          "source": "n_ot_cyclosporine",
          "target": "n_rp",
          "relation": "involved_in",
          "weight": 0.7,
          "agent": "Skeptic",
          "rationale": "风险通路关联"
        },
        {
          "source": "n_ot_methotrexate",
          "target": "n_rp",
          "relation": "involved_in",
          "weight": 0.7,
          "agent": "Skeptic",
          "rationale": "风险通路关联"
        },
        {
          "source": "n_ot_adalimumab",
          "target": "n_rp",
          "relation": "involved_in",
          "weight": 0.7,
          "agent": "Skeptic",
          "rationale": "风险通路关联"
        },
        {
          "source": "n_ot_il17_inhibitors",
          "target": "n_rp",
          "relation": "involved_in",
          "weight": 0.7,
          "agent": "Skeptic",
          "rationale": "风险通路关联"
        },
        {
          "source": "n_ot_topical_corticosteroids",
          "target": "n_rp",
          "relation": "involved_in",
          "weight": 0.7,
          "agent": "Skeptic",
          "rationale": "风险通路关联"
        },
        {
          "source": "n_ot_ustekinumab",
          "target": "n_rp",
          "relation": "involved_in",
          "weight": 0.7,
          "agent": "Skeptic",
          "rationale": "风险通路关联"
        },
        {
          "source": "n_ot_thalidomide",
          "target": "n_rp",
          "relation": "involved_in",
          "weight": 0.7,
          "agent": "Skeptic",
          "rationale": "风险通路关联"
        },
        {
          "source": "n_rp",
          "target": "n_adv",
          "relation": "causes",
          "weight": 0.7,
          "agent": "Skeptic",
          "rationale": "导致不良表型"
        },
        {
          "source": "n_adv",
          "target": "H1",
          "relation": "refutes",
          "weight": 0.8,
          "agent": "Skeptic",
          "rationale": "若该风险成立，抵消治疗获益"
        },
        {
          "source": "n_adv",
          "target": "H2",
          "relation": "refutes",
          "weight": 0.8,
          "agent": "Skeptic",
          "rationale": "若该风险成立，抵消治疗获益"
        },
        {
          "source": "n_adv",
          "target": "H3",
          "relation": "refutes",
          "weight": 0.8,
          "agent": "Skeptic",
          "rationale": "若该风险成立，抵消治疗获益"
        },
        {
          "source": "n_adv",
          "target": "H4",
          "relation": "refutes",
          "weight": 0.8,
          "agent": "Skeptic",
          "rationale": "若该风险成立，抵消治疗获益"
        },
        {
          "source": "n_adv",
          "target": "H5",
          "relation": "refutes",
          "weight": 0.8,
          "agent": "Skeptic",
          "rationale": "若该风险成立，抵消治疗获益"
        },
        {
          "source": "n_adv",
          "target": "H6",
          "relation": "refutes",
          "weight": 0.8,
          "agent": "Skeptic",
          "rationale": "若该风险成立，抵消治疗获益"
        },
        {
          "source": "n_adv",
          "target": "H7",
          "relation": "refutes",
          "weight": 0.8,
          "agent": "Skeptic",
          "rationale": "若该风险成立，抵消治疗获益"
        },
        {
          "source": "n_adv",
          "target": "H8",
          "relation": "refutes",
          "weight": 0.8,
          "agent": "Skeptic",
          "rationale": "若该风险成立，抵消治疗获益"
        },
        {
          "source": "n_adv",
          "target": "H9",
          "relation": "refutes",
          "weight": 0.8,
          "agent": "Skeptic",
          "rationale": "若该风险成立，抵消治疗获益"
        },
        {
          "source": "n_adv",
          "target": "H10",
          "relation": "refutes",
          "weight": 0.8,
          "agent": "Skeptic",
          "rationale": "若该风险成立，抵消治疗获益"
        },
        {
          "source": "n_adv",
          "target": "H11",
          "relation": "refutes",
          "weight": 0.8,
          "agent": "Skeptic",
          "rationale": "若该风险成立，抵消治疗获益"
        },
        {
          "source": "n_adv",
          "target": "H12",
          "relation": "refutes",
          "weight": 0.8,
          "agent": "Skeptic",
          "rationale": "若该风险成立，抵消治疗获益"
        }
      ],
      "round_index": 1
    },
    "history": {
      "round": 1,
      "last_scores": [
        {
          "hypothesis_id": "H1",
          "score": 0.63,
          "components": {
            "mechanism_fit": 0.75,
            "class_prior": 0.5,
            "pk_pd_feasibility": 0.6,
            "indication_plausibility": 0.8,
            "safety_risk": 0.2,
            "graph_bonus": 0.15,
            "conflict_penalty": 0.15
          },
          "graph_signals": {
            "support_weight": 0.85,
            "contradiction_weight": 0.8,
            "mechanistic_connectivity": true,
            "path_disjointness": 1,
            "conflict_hotspots": [
              {
                "topic": "风险通路与不良表型",
                "pro": [],
                "con": [
                  "n_adv"
                ]
              }
            ]
          },
          "rationales": {
            "mechanism_fit": [
              "Acitretin 作用于炎症通路，支撑与 GPP 相关"
            ],
            "indication_plausibility": [
              "对 GPP 患者通常有效"
            ],
            "safety_risk": [
              "存在较高的反对边，指出潜在的不良反应"
            ]
          },
          "confidence": "medium",
          "uncertainties": [
            "安全性问题需进一步验证"
          ]
        },
        {
          "hypothesis_id": "H2",
          "score": 0.61,
          "components": {
            "mechanism_fit": 0.7,
            "class_prior": 0.5,
            "pk_pd_feasibility": 0.5,
            "indication_plausibility": 0.8,
            "safety_risk": 0.2,
            "graph_bonus": 0.15,
            "conflict_penalty": 0.15
          },
          "graph_signals": {
            "support_weight": 0.85,
            "contradiction_weight": 0.8,
            "mechanistic_connectivity": true,
            "path_disjointness": 1,
            "conflict_hotspots": [
              {
                "topic": "风险通路与不良表型",
                "pro": [],
                "con": [
                  "n_adv"
                ]
              }
            ]
          },
          "rationales": {
            "mechanism_fit": [
              "Apremilast 调节免疫，有助于 GPP 治疗"
            ],
            "indication_plausibility": [
              "已有临床数据支持其有效性"
            ],
            "safety_risk": [
              "存在较高的反对边，指出潜在的不良反应"
            ]
          },
          "confidence": "medium",
          "uncertainties": [
            "临床特异性尚需更多证据"
          ]
        },
        {
          "hypothesis_id": "H3",
          "score": 0.65,
          "components": {
            "mechanism_fit": 0.8,
            "class_prior": 0.5,
            "pk_pd_feasibility": 0.6,
            "indication_plausibility": 0.8,
            "safety_risk": 0.2,
            "graph_bonus": 0.15,
            "conflict_penalty": 0.15
          },
          "graph_signals": {
            "support_weight": 0.85,
            "contradiction_weight": 0.8,
            "mechanistic_connectivity": true,
            "path_disjointness": 1,
            "conflict_hotspots": [
              {
                "topic": "风险通路与不良表型",
                "pro": [],
                "con": [
                  "n_adv"
                ]
              }
            ]
          },
          "rationales": {
            "mechanism_fit": [
              "Etanercept 靶向 TNF-α，适合 GPP 治疗"
            ],
            "indication_plausibility": [
              "相关文献支持其用于炎症性疾病"
            ],
            "safety_risk": [
              "高风险的潜在不良反应可能影响治疗"
            ]
          },
          "confidence": "medium",
          "uncertainties": [
            "暴露风险效应的临床数据不足"
          ]
        },
        {
          "hypothesis_id": "H4",
          "score": 0.64,
          "components": {
            "mechanism_fit": 0.8,
            "class_prior": 0.5,
            "pk_pd_feasibility": 0.5,
            "indication_plausibility": 0.8,
            "safety_risk": 0.2,
            "graph_bonus": 0.15,
            "conflict_penalty": 0.15
          },
          "graph_signals": {
            "support_weight": 0.85,
            "contradiction_weight": 0.8,
            "mechanistic_connectivity": true,
            "path_disjointness": 1,
            "conflict_hotspots": [
              {
                "topic": "风险通路与不良表型",
                "pro": [],
                "con": [
                  "n_adv"
                ]
              }
            ]
          },
          "rationales": {
            "mechanism_fit": [
              "Infliximab 有效针对炎症，适合 GPP"
            ],
            "indication_plausibility": [
              "存在针对 GPP 的研究数据支持"
            ],
            "safety_risk": [
              "潜在的不良反应需重视"
            ]
          },
          "confidence": "medium",
          "uncertainties": [
            "长期使用安全性有待验证"
          ]
        },
        {
          "hypothesis_id": "H5",
          "score": 0.66,
          "components": {
            "mechanism_fit": 0.75,
            "class_prior": 0.5,
            "pk_pd_feasibility": 0.5,
            "indication_plausibility": 0.8,
            "safety_risk": 0.2,
            "graph_bonus": 0.15,
            "conflict_penalty": 0.15
          },
          "graph_signals": {
            "support_weight": 0.85,
            "contradiction_weight": 0.8,
            "mechanistic_connectivity": true,
            "path_disjointness": 1,
            "conflict_hotspots": [
              {
                "topic": "风险通路与不良表型",
                "pro": [],
                "con": [
                  "n_adv"
                ]
              }
            ]
          },
          "rationales": {
            "mechanism_fit": [
              "Secukinumab 作为 IL-17 抑制剂，调节免疫"
            ],
            "indication_plausibility": [
              "相关研究表明其对 GPP 有益"
            ],
            "safety_risk": [
              "存在潜在不良表型的风险"
            ]
          },
          "confidence": "medium",
          "uncertainties": [
            "CC对神经系统影响的长期研究短缺"
          ]
        },
        {
          "hypothesis_id": "H6",
          "score": 0.59,
          "components": {
            "mechanism_fit": 0.6,
            "class_prior": 0.5,
            "pk_pd_feasibility": 0.5,
            "indication_plausibility": 0.7,
            "safety_risk": 0.2,
            "graph_bonus": 0.15,
            "conflict_penalty": 0.15
          },
          "graph_signals": {
            "support_weight": 0.75,
            "contradiction_weight": 0.8,
            "mechanistic_connectivity": true,
            "path_disjointness": 1,
            "conflict_hotspots": [
              {
                "topic": "风险通路与不良表型",
                "pro": [],
                "con": [
                  "n_adv"
                ]
              }
            ]
          },
          "rationales": {
            "mechanism_fit": [
              "Cyclosporine 有免疫抑制的作用"
            ],
            "indication_plausibility": [
              "在某些自身免疫性疾病中有效"
            ],
            "safety_risk": [
              "与不良表型有关的风险"
            ]
          },
          "confidence": "medium",
          "uncertainties": [
            "适应症上限及有效性数据缺乏"
          ]
        },
        {
          "hypothesis_id": "H7",
          "score": 0.58,
          "components": {
            "mechanism_fit": 0.6,
            "class_prior": 0.5,
            "pk_pd_feasibility": 0.5,
            "indication_plausibility": 0.7,
            "safety_risk": 0.2,
            "graph_bonus": 0.15,
            "conflict_penalty": 0.15
          },
          "graph_signals": {
            "support_weight": 0.75,
            "contradiction_weight": 0.8,
            "mechanistic_connectivity": true,
            "path_disjointness": 1,
            "conflict_hotspots": [
              {
                "topic": "风险通路与不良表型",
                "pro": [],
                "con": [
                  "n_adv"
                ]
              }
            ]
          },
          "rationales": {
            "mechanism_fit": [
              "Methotrexate 在发生治疗响应中有一定效果"
            ],
            "indication_plausibility": [
              "被用作其他自身免疫病的治疗"
            ],
            "safety_risk": [
              "与不良表型风险相关"
            ]
          },
          "confidence": "medium",
          "uncertainties": [
            "效果持续时间和耐受性尚未完全了解"
          ]
        },
        {
          "hypothesis_id": "H8",
          "score": 0.6,
          "components": {
            "mechanism_fit": 0.65,
            "class_prior": 0.5,
            "pk_pd_feasibility": 0.6,
            "indication_plausibility": 0.7,
            "safety_risk": 0.2,
            "graph_bonus": 0.15,
            "conflict_penalty": 0.15
          },
          "graph_signals": {
            "support_weight": 0.75,
            "contradiction_weight": 0.8,
            "mechanistic_connectivity": true,
            "path_disjointness": 1,
            "conflict_hotspots": [
              {
                "topic": "风险通路与不良表型",
                "pro": [],
                "con": [
                  "n_adv"
                ]
              }
            ]
          },
          "rationales": {
            "mechanism_fit": [
              "Adalimumab 针对 TNF-α，有助于减轻炎症"
            ],
            "indication_plausibility": [
              "在多种炎症性疾病中证实有效"
            ],
            "safety_risk": [
              "需要关注潜在的不良效果"
            ]
          },
          "confidence": "medium",
          "uncertainties": [
            "长期疗效和安全性需进一步明确"
          ]
        },
        {
          "hypothesis_id": "H9",
          "score": 0.67,
          "components": {
            "mechanism_fit": 0.75,
            "class_prior": 0.5,
            "pk_pd_feasibility": 0.6,
            "indication_plausibility": 0.8,
            "safety_risk": 0.2,
            "graph_bonus": 0.15,
            "conflict_penalty": 0.15
          },
          "graph_signals": {
            "support_weight": 0.85,
            "contradiction_weight": 0.8,
            "mechanistic_connectivity": true,
            "path_disjointness": 1,
            "conflict_hotspots": [
              {
                "topic": "风险通路与不良表型",
                "pro": [],
                "con": [
                  "n_adv"
                ]
              }
            ]
          },
          "rationales": {
            "mechanism_fit": [
              "IL-17 抑制剂具有免疫调节作用"
            ],
            "indication_plausibility": [
              "有效性得到前期研究验证"
            ],
            "safety_risk": [
              "可能携带的不良反应需慎重评估"
            ]
          },
          "confidence": "medium",
          "uncertainties": [
            "长期使用对有风险患者的影响不明确"
          ]
        },
        {
          "hypothesis_id": "H10",
          "score": 0.54,
          "components": {
            "mechanism_fit": 0.6,
            "class_prior": 0.5,
            "pk_pd_feasibility": 0.5,
            "indication_plausibility": 0.6,
            "safety_risk": 0.2,
            "graph_bonus": 0.15,
            "conflict_penalty": 0.15
          },
          "graph_signals": {
            "support_weight": 0.75,
            "contradiction_weight": 0.8,
            "mechanistic_connectivity": true,
            "path_disjointness": 1,
            "conflict_hotspots": [
              {
                "topic": "风险通路与不良表型",
                "pro": [],
                "con": [
                  "n_adv"
                ]
              }
            ]
          },
          "rationales": {
            "mechanism_fit": [
              "局部皮质类固醇通常用于治疗皮肤炎症"
            ],
            "indication_plausibility": [
              "快速缓解 GPP 的症状"
            ],
            "safety_risk": [
              "需关注随空间分布引起的潜在风险"
            ]
          },
          "confidence": "medium",
          "uncertainties": [
            "局部使用效应以外的潜在影响缺少明确性"
          ]
        },
        {
          "hypothesis_id": "H11",
          "score": 0.62,
          "components": {
            "mechanism_fit": 0.75,
            "class_prior": 0.5,
            "pk_pd_feasibility": 0.6,
            "indication_plausibility": 0.8,
            "safety_risk": 0.2,
            "graph_bonus": 0.15,
            "conflict_penalty": 0.15
          },
          "graph_signals": {
            "support_weight": 0.85,
            "contradiction_weight": 0.8,
            "mechanistic_connectivity": true,
            "path_disjointness": 1,
            "conflict_hotspots": [
              {
                "topic": "风险通路与不良表型",
                "pro": [],
                "con": [
                  "n_adv"
                ]
              }
            ]
          },
          "rationales": {
            "mechanism_fit": [
              "Ustekinumab 靶向 IL-12/23 途径，调节免疫反应"
            ],
            "indication_plausibility": [
              "在某些 GPP 老年患者中显示效果"
            ],
            "safety_risk": [
              "多个反对点需要高关注"
            ]
          },
          "confidence": "medium",
          "uncertainties": [
            "后续临床数据可能影响疗效"
          ]
        },
        {
          "hypothesis_id": "H12",
          "score": 0.55,
          "components": {
            "mechanism_fit": 0.6,
            "class_prior": 0.5,
            "pk_pd_feasibility": 0.5,
            "indication_plausibility": 0.6,
            "safety_risk": 0.2,
            "graph_bonus": 0.15,
            "conflict_penalty": 0.15
          },
          "graph_signals": {
            "support_weight": 0.75,
            "contradiction_weight": 0.8,
            "mechanistic_connectivity": true,
            "path_disjointness": 1,
            "conflict_hotspots": [
              {
                "topic": "风险通路与不良表型",
                "pro": [],
                "con": [
                  "n_adv"
                ]
              }
            ]
          },
          "rationales": {
            "mechanism_fit": [
              "Thalidomide 有抗炎和免疫调节作用"
            ],
            "indication_plausibility": [
              "在特定情况下的疗效有所报道"
            ],
            "safety_risk": [
              "需关注潜在的严重不良反应"
            ]
          },
          "confidence": "medium",
          "uncertainties": [
            "证据基础相对较弱"
          ]
        }
      ]
    },
    "thresholds": {
      "stop_delta": 0.03,
      "saturation_ratio": 0.65,
      "weights": {
        "path_disjointness": 1.0
      }
    },
    "ablation_config": {
      "enable_debate": true,
      "enable_skeptic": true,
      "enable_pi_interrupts": true,
      "enable_textual_feedback": true,
      "enable_heuristic_transfer": true,
      "enable_seed_regen": true,
      "weights": {
        "path_disjointness": 1.0
      },
      "mode": "graph"
    }
  },
  "output": {
    "revisions": [
      {
        "hypothesis_id": "H1",
        "graph_actions": [
          {
            "type": "add_mechanism_link",
            "from": "Acitretin",
            "via": [
              "Inflammation Pathway"
            ],
            "to": "Generalised pustular psoriasis",
            "success_criteria": "形成至少2条不相交路径",
            "assignee": "Proponent"
          },
          {
            "type": "stress_test_safety",
            "topic": "风险通路与不良表型",
            "expectation": "若风险成立，标注高权重 refutes 边",
            "assignee": "Skeptic"
          }
        ],
        "debate_focus": [
          "探讨 Acitretin 的安全性与不良反应",
          "澄清 GPP 的合并症及影响因素"
        ]
      },
      {
        "hypothesis_id": "H2",
        "graph_actions": [
          {
            "type": "add_mechanism_link",
            "from": "Apremilast",
            "via": [
              "Immunomodulation Pathway"
            ],
            "to": "Generalised pustular psoriasis",
            "success_criteria": "形成至少2条不相交路径",
            "assignee": "Proponent"
          },
          {
            "type": "stress_test_safety",
            "topic": "风险通路与不良表型",
            "expectation": "若风险成立，标注高权重 refutes 边",
            "assignee": "Skeptic"
          }
        ],
        "debate_focus": [
          "证实 Apremilast 对 GPP 治疗的效果",
          "讨论潜在的安全性问题"
        ]
      }
    ],
    "pruned_hypotheses": [],
    "new_subhypotheses": [],
    "seed_request": {
      "should_regenerate": true,
      "reason": "当前候选假设支持薄弱，冲突高且路径独立性不足，需引入更多候选以提高图的完整性。",
      "n": 4
    }
  }
}